A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, Phase II, placebo-controlled trial adding on to a
background of effective treatment designed to evaluate the efficacy, safety, and
pharmacokinetics of PRO95780 combined with paclitaxel + carboplatin + bevacizumab therapy in
patients with previously untreated Stage IIIB, Stage IV, or recurrent non-small cell lung
cancer (NSCLC). Approximately 120 patients will be randomized to one of two treatment arms.